In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

First Horizon gets rights to AstraZeneca's Sular

Executive Summary

AstraZeneca UK Ltd. has licensed US rights to the antihypertensive drug nisoldipine (Sular) to cardiovascular and GI drug company First Horizon Pharmaceutical. The deal is valued at approximately $185mm, plus up to $30mm payable to AstraZeneca on achievement of certain performance milestones.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies